Shopping cart processing ...
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Customer Support 24/7
USA/Canada Toll Free USA
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Your cart: $0.00 (0 items)

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!


  • Michael Brandtner Redding, CA, USA
    Thanks to my friends for suggesting me this site. Now I can order the drugs I am interested in without prescription and at lower cost.
More info »


Bimatoprost reduces increased intraocular pressure in open-angle glaucoma and ophthalmic hypertension in adults

Brand: Bimatoprost

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: June 2024
View product image
Package Price Per pill Save Order
Bimatoprost 0.03% ml
9 bottles - 0.03% ml
+ 8 free Viagra 100 mg, 5% discount for future orders
$251.15 $27.91 $30.82 Add to cart
8 bottles - 0.03% ml
+ 8 free Viagra 100 mg, 5% discount for future orders
$223.65 $27.96 $26.99 Add to cart
7 bottles - 0.03% ml
+ 4 free Viagra 100 mg, 3% discount for future orders
$196.15 $28.02 $23.16 Add to cart
6 bottles - 0.03% ml
+ 4 free Viagra 100 mg, 3% discount for future orders
$168.55 $28.09 $19.43 Add to cart
5 bottles - 0.03% ml
+ 4 free Viagra 100 mg, 3% discount for future orders
$140.99 $28.20 $15.66 Add to cart
4 bottles - 0.03% ml
+ 4 free Viagra 100 mg, 3% discount for future orders
$113.39 $28.35 $11.93 Add to cart
3 bottles - 0.03% ml $85.73 $28.58 $8.26 Add to cart
2 bottles - 0.03% ml $57.51 $28.76 $5.15 Add to cart
1 bottles - 0.03% ml $31.33 $31.33 No Add to cart

Product description

Pharmacodynamics of Bimatoprost

Buy Bimatoprost in canada

Bimatoprost reduces IOP in humans by increasing the outflow of aqueous humor through the trabecular network and uveoscleral outflow. The decrease in IOP begins about 4 hours after the first application and the maximum effect is achieved after about 8-12 hours. The effect lasts for at least 24 hours.

Bimatoprost is a potent ophthalmic antihypertensive agent. It is a synthetic prostamide, structurally linked to PGF2alpha, which does not act through the known PG receptors. Bimatoprost selectively mimics the effects of recently discovered biosynthesized substances, prostamides. However, the structure of prostamide receptors has not yet been identified.

Limited information is available on the effectiveness of bimatoprost in the treatment of pseudoexfoliative and pigmentary glaucoma, as well as on the experience of using bimatoprost in the treatment of angle-closure glaucoma in patients who have previously undergone iridotomy.

According to clinical studies, there was no significant effect of bimatoprost on heart rate and blood pressure.

In the treatment of hypotrichosis, the exact mechanism of action of bimatoprost is unknown, however, it is assumed that eyelash growth occurs due to an increase in the number of eyelashes, as well as an increase in the duration of the hair follicle growth phase or the eyelash growth phase.

Children. There are no data on the efficacy and safety of using bimatoprost in patients under 18 years of age.

Pharmacokinetics of Bimatoprost

Treatment of eye problems with Bimatoprost

Absorption. Bimatoprost penetrates well into the cornea and sclera of the human eye in vitro. When instilling in adults, the systemic exposure of bimatoprost is very small, no accumulation of drugs was noted. After applying a 0.03% solution of bimatoprost, 1 drop in both eyes once a day for 2 weeks Cmax in the blood was reached within 10 minutes after instillation, and within 1.5 hours this indicator was below the detection level (0.025 ng / ml). The average Cvalues ​​ofmax and AUC0-24 were approximately the same on the 7th and 14th days - approximately 0.08 ng / ml and 0.09 ng · h / ml, respectively, indicating that the Css of bimatoprost was achieved during the first week of instillations.

Distribution. Bimatoprost is moderately distributed in the tissues of the body, systemic Vss - 0.67 l / kg. In human blood, bimatoprost is found mainly in plasma. Plasma protein binding of bimatoprost is about 88%.

Metabolism. Bimatoprost reaches the systemic circulation mainly unchanged. Then oxidation, N-deethylation and glucuronization occurs with the formation of a number of metabolites.

Excretion. Bimatoprost is excreted mainly through the kidneys. Up to 67% of the intravenous dose administered in healthy adult volunteers was excreted in the urine, 25% of the dose was excreted in the feces. T1/ 2 after intravenous administration was approximately 45 minutes; total clearance from blood - 1.5 l / h / kg.

Application of the substance Bimatoprost

Packaging of the drug Bimatoprost

Decrease in increased IOP in open-angle glaucoma and ophthalmic hypertension in adults (as monotherapy or in combination with beta-blockers).

Treatment of hypotrichosis of the eyelashes (insufficient eyelash growth).


Special studies of interaction with other drugs have not been conducted. No interaction is expected in the human body, as systemic concentrations of bimatoprost are extremely low (less than 0.2 ng / ml) after topical application of bimatoprost in ophthalmology.

In clinical studies, bimatoprost was used in conjunction with several different beta-blockers for topical use in ophthalmology, but no interaction was observed.

The simultaneous use of bimatoprost and other antiglaucoma drugs, except for ophthalmic beta-blockers, has not been studied in the course of studies of the effectiveness and safety of combination therapy.

There was a decrease in the hypotensive effect of bimatoprost in the form of eye drops when used together with other analogs of PG in the treatment of ophthalmic hypertension or glaucoma.


There have been no cases of overdose with topical application.

In case of overdose, treatment should be symptomatic and supportive.

Routes of administration

Conjunctivally, locally.

Precautions for Bimatoprost Substance

Effect on IOP. Bimatoprost reduces IOP when it is instilled directly into the conjunctival cavity of patients with increased IOP. In clinical studies, the use of bimatoprost in the form of drops for topical application was accompanied by a decrease in IOP both in patients with high IOP and with its normal values, but did not reach clinically significant values. With the combined use of bimatoprost in the form of drops for topical use and analogs of PG (including bimatoprost in the form of eye drops) used to reduce IOP in patients with intraocular hypertension, a decrease in the hypotensive effect is possible. If the patient receives treatment with analogs of PG, consultation with the attending physician and monitoring of IOP are necessary when prescribing additional therapy with bimatoprost in the form of drops for topical application.

At-risk groups. Caution should be exercised when used in patients with acute inflammatory diseases of the inner membranes of the eyeball, for example, with uveitis (since the use of bimatoprost may aggravate the course of inflammation), in patients with aphakia, pseudoaphakia with rupture of the posterior lens capsule or with risk factors for the development of macular edema.

Pigmentation of the iris. An increase in the pigmentation of the iris of the eye is possible, especially with dark pigments, this effect may be irreversible. An increase in the pigmentation of the iris was observed with the instillation of eye drops. Changes in pigmentation are primarily associated with an increase in melanin content, as well as an increase in the number of melanocytes. The duration of the pigmentation enhancing effect is unknown. Changes in the color of the iris during treatment may go unnoticed for a period from several months to several years. There is no evidence of the clinical relevance of increased iris pigmentation in the long term. As a rule, when using bimatoprost, brown pigmentation around the pupil spreads concentrically to the periphery of the iris, as a result of which the entire iris or individual sectors acquire a brownish color. The use of bimatoprost does not affect the accumulation of pigment in the iris of the eye (nevi and freckles). A significant increase in the pigmentation of the iris is not an indication for the cancellation of bimatoprost in the form of drops for topical application.

Eyelid skin pigmentation. Bimatoprost has been reported to cause darkening of the eyelids and periorbital region.

It is assumed that pigmentation may increase during the entire period of use of bimatoprost, but in most patients it is reversible and gradually disappears when the drug is discontinued.

Hair growth outside the treatment area. Hair growth is possible on those areas of the skin to which bimatoprost was accidentally applied in the form of drops for topical application. It is important to apply the drugs only to the skin of the edge of the upper eyelid along the lash line using the supplied sterile applicator; avoid contact with facial skin.

In case of any symptoms on the part of the organ of vision (including an eye injury, an infectious complication), with a sudden decrease in visual acuity, the need for a planned ophthalmic operation, as well as in the event of undesirable reactions, you should contact an ophthalmologist to resolve the issue of the possibility of further treatment with bimatoprost.

With hypotrichosis of the eyelashes, the effect of treatment develops gradually, in most patients within 2 months. Patients should be warned that the effect of bimatoprost is inconsistent, and a gradual return to the initial state is expected after discontinuation of drug use. In addition, there may be differences in the length of the eyelashes, their thickness, color intensity, the total number of eyelashes or uneven growth, and / or a change in the direction of eyelash growth.

Influence on the ability to drive vehicles and work with mechanisms. Bimatoprost has little effect on the ability to drive and operate machinery. As with the use of other eye drops, if temporary blurred vision occurs after instillation, it is necessary to wait until the clarity of visual perception is restored before driving or operating machinery.

Side effects of the substance Bimatoprost

When used as an anti-glaucoma drug

The following undesirable effects were observed during clinical studies of bimatoprost in the form of 0.03% eye drops and in the post-registration period.

Frequency of occurrence is given in accordance with the following classification: very common (≥1 / 10); often (≥1 / 100 to </ 10); infrequently (≥1 / 1000 to <1/100); rarely (≥1 / 10,000 to <1 / 1,000); very rare (<1/10000) and with unknown frequency (cannot be estimated from available data).

In each group, adverse effects are presented in order of decreasing severity.

From the nervous system: often - headache; infrequently - dizziness.

From the side of the organs of vision: very often - injection of conjunctival vessels, itching in the eyes, growth of eyelashes; often - superficial punctate keratitis, corneal erosion, burning in the eyes, eye irritation, allergic conjunctivitis, blepharitis, decreased visual acuity, dryness of the mucous membrane of the eyes, redness of the eyelids, pain in the eyes, photophobia, discharge from the eyes, blurred vision, itching of the eyelid skin, decreased visual acuity, asthenopia, conjunctival edema, foreign body sensation in the eye, dry eye, eye pain, photophobia, lacrimation, eye discharge, visual impairment, increased iris pigmentation, darkened eyelashes; infrequently - retinal hemorrhagic disorders, uveitis, cystic macular edema, iritis, blepharospasm, eyelid retraction, periorbital erythema; with an unknown frequency - enophthalmos.

From the side of the vessels: often - hypertension.

On the part of the skin and subcutaneous tissues: infrequently - hirsutism.

General disorders and disorders at the injection site: infrequently - asthenia.

Data from laboratory and instrumental studies: often - a deviation from the norm of biochemical parameters of liver function.

In very rare cases, corneal calcification has been observed with the use of phosphate-containing eye drops in patients with concomitant significant damage to the cornea.

When used as a drug for the treatment of eyelash hypotrichosis

General information on adverse reactions when using bimatoprost in the form of 0.03% topical drops were obtained in a multicenter, randomized, double-blind, placebo-controlled study in parallel groups involving 278 adult patients who received therapy with the studied drugs for 4 months.

Itchy eyes, conjunctival hyperemia, eyelid hyperpigmentation, eye irritation, dry eye syndrome, eyelid redness. The listed adverse reactions were observed in less than 4% of cases.

The frequency of occurrence of adverse events according to the data of post-registration use cannot be determined due to the lack of information on the size of the population in which the development of each of the adverse events was noted, as well as the spontaneous nature of reports of adverse events in this period. Additionally, in the post-registration period, the following adverse reactions were reported: burning sensation of the eyelids, swelling of the conjunctiva, irritation of the eyelids, edema of the eyelids, itching of the eyelid skin, hyperpigmentation of the iris, hypersensitivity reactions (local allergic reactions), lacrimation, madarosis and trichorrhexis (temporary loss of eyelashes from several pieces to whole areas and temporary fragility of the eyelashes, respectively), changes in the skin of the eyelids and periorbital area, including deepening of the eyelid fold, spotty rash or erythematous rash, skin discoloration (periorbital), blurred vision.